Fausto Castagnetti Selected Research

Fausto Castagnetti Research Topics

Disease

90	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 10/2022 - 12/2004
9	Philadelphia Chromosome 01/2021 - 11/2006
8	Leukemia 01/2021 - 11/2006
4	Neoplasms (Cancer) 11/2020 - 01/2017
4	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2019 - 12/2006
4	Blast Crisis (Blast Phase) 04/2015 - 06/2005
4	Chromosome Aberrations (Chromosome Abnormalities) 06/2014 - 01/2009
3	Infections 01/2022 - 01/2018
3	Pleural Effusion (Pleural Effusions) 01/2018 - 10/2011
2	Pathologic Complete Response 02/2009 - 12/2008
1	Bronchiolitis Obliterans Syndrome 01/2022
1	Dyslipidemias (Dyslipidemia) 08/2021
1	Necrosis 12/2020
1	Pseudomonas Infections 12/2020
1	Sepsis (Septicemia) 12/2020
1	Hypertension (High Blood Pressure) 07/2020
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2020
1	Hematologic Diseases (Blood Diseases) 12/2019
1	Frailty 05/2018
1	Primary Myelofibrosis (Myelosclerosis) 05/2018
1	Fatigue 01/2018
1	Disease Resistance 01/2017
1	Thrombosis (Thrombus) 09/2015
1	Muscle Cramp (Cramp) 10/2014
1	Anemia 10/2014
1	Exanthema (Rash) 10/2014
1	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 09/2013
1	Lung Diseases (Lung Disease) 06/2013
1	Residual Neoplasm 05/2013
1	Head and Neck Neoplasms (Head and Neck Cancer) 10/2011
1	Breast Neoplasms (Breast Cancer) 10/2011
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2011
1	Lung Neoplasms (Lung Cancer) 10/2011
1	Hematologic Neoplasms (Hematological Malignancy) 06/2010
1	Pancreatitis 12/2009

Drug/Important Bio-Agent (IBA)

51	Imatinib Mesylate (Gleevec)FDA Link 01/2020 - 12/2004
38	Tyrosine Kinase InhibitorsIBA 06/2022 - 12/2008
23	nilotinib FDA Link 10/2022 - 06/2007
16	Dasatinib (BMS 354825)FDA Link 01/2020 - 11/2006
8	Pharmaceutical PreparationsIBA 07/2020 - 10/2011
8	Phosphotransferases (Kinase)IBA 01/2020 - 06/2005
6	ponatinibIBA 01/2021 - 09/2018
4	CateninsIBA 10/2017 - 09/2013
3	Proteins (Proteins, Gene)FDA Link 01/2021 - 11/2017
3	Interferon-alpha (Interferon Alfa)IBA 08/2010 - 12/2004
2	LDL Lipoproteins (beta Lipoproteins)IBA 08/2021 - 01/2020
2	amsonic acid (DAS)IBA 01/2018 - 01/2016
2	bcr-abl Fusion ProteinsIBA 07/2017 - 09/2013
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2015 - 09/2013
2	Lipase (Acid Lipase)FDA Link 12/2009 - 12/2009
1	Dihydroorotate DehydrogenaseIBA 06/2022
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 08/2021
1	oxidized low density lipoproteinIBA 08/2021
1	tazobactam drug combination ceftolozaneIBA 12/2020
1	Tazobactam Drug Combination Piperacillin (Zosyn)FDA LinkGeneric 12/2020
1	Meropenem (Merrem)FDA LinkGeneric 12/2020
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 07/2020
1	Angiotensin Receptor AntagonistsIBA 07/2020
1	Aurora Kinase AIBA 04/2020
1	Triglycerides (Triacylglycerol)IBA 01/2020
1	LDL CholesterolIBA 01/2020
1	bosutinibIBA 01/2019
1	ruxolitinibIBA 05/2018
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2018
1	posaconazole FDA Link 01/2018
1	Transcription Factors (Transcription Factor)IBA 11/2017
1	ChromatinIBA 11/2017
1	Polo-Like Kinase 1IBA 11/2017
1	MethyltransferasesIBA 04/2015
1	DNA (Deoxyribonucleic Acid)IBA 04/2015
1	Busulfan (Busulfex)FDA Link 01/2014
1	Hydroxyurea (Hydrea)FDA LinkGeneric 01/2014
1	Glycogen Synthase Kinase 3IBA 09/2013
1	Tyr sulfate(1)- enkephalinamide-Leu (LETS)IBA 01/2013
1	beta CateninIBA 01/2013
1	SuspensionsIBA 10/2011
1	EnzymesIBA 12/2009
1	Amylases FDA Link 12/2009
1	Biomarkers (Surrogate Marker)IBA 02/2009
1	Interferon-alpha2bIBA 12/2004

Therapy/Procedure

28	Therapeutics 01/2022 - 12/2008
3	Stem Cell Transplantation 05/2013 - 12/2008
1	Secondary Prevention 01/2019
1	Contraindications 05/2018
1	Drug Therapy (Chemotherapy) 01/2018
1	Polypharmacy 11/2016
1	Drug Tapering 10/2014
1	Hematopoietic Stem Cell Transplantation 05/2013